SOUTH EASTON, Mass., March 10 /PRNewswire-FirstCall/ -- Pressure
BioSciences, Inc. (Nasdaq: PBIO) today announced that it has moved its
corporate offices to 14 Norfolk Avenue in South Easton, Massachusetts. This
move was necessary to accommodate the Company's transition from an
early-stage, research and development company to a fully commercial
operation. Richard T. Schumacher, PBI's Founder, President, and CEO
commented: "We now have approximately 5,500 square feet, with sufficient
office, conference, engineering lab, and storage space to allow us to
better develop our infrastructure to support our PCT product
commercialization. In addition, the 18 month lease, with equal term
extension, gives us the financial flexibility we require as we continue to
grow our business and carefully manage our financial resources". The
Company's primary research and development facility continues to be located
at 6 Gill Street in Woburn, MA.
Pressure BioSciences, Inc
14 Norfolk Avenue
South Easton, MA 02375
(t) (508) 230-1828
(f) (508) 230-1829
Research and Development Center
Pressure BioSciences, Inc
6 Gill Street, Suite H
Woburn, MA 01801
(t) (781) 932-9477
(f) (781) 932-9294
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's
intentions, hopes, beliefs, expectations, or predictions of the future are
"forward-looking'' statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are based upon the
Company's current expectations, forecasts, and assumptions that are subject
to risks, uncertainties, and other factors that could cause actual outcomes
and results to differ materially from those indicated by these
forward-looking statements. These risks, uncertainties, and other factors
include, but are not limited to, risks and uncertainties discussed under
the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB
for the year ended December 31, 2006, and other reports filed by the
Company from time to time with the SEC. The Company undertakes no
obligation to update any of the information included in this release,
except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.
Edward H. Myles,
Senior Vice President of Finance & CFO (T) 508-230-1828
|SOURCE Pressure BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved